期刊文献+

卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌的效果比较 被引量:20

下载PDF
导出
摘要 目的观察卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌的临床效果。方法将进展期胃癌患者100例分为两组,卡培他滨联合奥沙利铂治疗的为卡组50例,替吉奥联合奥沙利铂治疗的为吉组50例。结果卡组总有效率60%,吉组总有效率56%,两组总有效率比较差异均无统计学意义。结论卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌均能达到良好的临床疗效,较少的不良反应,都可以做为进展期胃癌化疗方案。
作者 李金燕
出处 《中国实用医药》 2013年第18期157-158,共2页 China Practical Medicine
  • 相关文献

参考文献4

二级参考文献12

  • 1李园,武晓勤,崔慧娟,谭煌英.紫杉醇联合化疗方案治疗晚期胃癌的临床研究[J].中华肿瘤杂志,2004,26(9):562-564. 被引量:19
  • 2钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 3库建伟,潘瑞华.奥沙利铂联合希罗达治疗晚期胃癌临床观察[J].山东医药,2007,47(1):55-55. 被引量:11
  • 4Greenlee RT,. Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin, 2000, 50:7-33.
  • 5Cunningham D, Starhng N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med, 2008, 358 : 36-46.
  • 6Lee SS, Lee JL, Ryn MH, et al. Combination chemotherapy with capecitabine( X ) and cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Jpn J Clin Oncol, 2007, 37:30-37.
  • 7Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with oxaliplatin (XELOX) as a first line therapy for advanced gastric cancer. Cancer Chemother Pharmacol, 2008,61:623-629.
  • 8Van Custem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line therapy for advanced gastric cancer: a report of the V325 study group. J Chn Oncol, 2006, 24:4991-4997.
  • 9Kang HJ, Chang HM, Kim TW, et al. A phase Ⅱ study of paclitaxel and capecitabine as a first line combination chemotherapy for advanced gastric cancer. Br J Cancer, 2008, 98:316-322.
  • 10孙燕.内科肿瘤学[M].北京:人民卫生出版社,2003.994-995.

共引文献35

同被引文献154

  • 1樊卫飞,王峻,孟丽娟,刘福银,蒲骁麟,杨民.替吉奥联合奥沙利铂一线治疗老年晚期胃癌的疗效分析[J].实用老年医学,2013,27(3):240-243. 被引量:12
  • 2张斌,陈虎.肿瘤免疫细胞治疗的质量管理和疗效评价[J].中国肿瘤生物治疗杂志,2015,22(1):8-15. 被引量:17
  • 3陈越磊,岑均达.卡培他滨类似物的合成及体内抗肿瘤活性[J].中国药物化学杂志,2004,14(5):277-279. 被引量:10
  • 4季加孚.我国胃癌防治研究三十年回顾[J].中国肿瘤临床,2013,40(22):1345-1351.
  • 5Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-l-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer [ J ]. Eur J Cancer, 2012, 48 (4) :518-526.
  • 6Shimma N, Umeda I, Arasaki M, et al. The design and synthesis of a new tumor-selective fluoropyrimidine carbamate, capecitabine [J]. Bioorg Med Chem,2000,8(7) :1697 -1706.
  • 7Miles D, Zielinski C, Martin M, et al. Combining capeeitabin: and bevacizumab in metastatic breast cancer: A comprehensive review [J]. European Journal of Cancer,2012,48(4) :482 -491.
  • 8季俊虬,高美华,李孝常,等.一种卡培他滨中间体的简便精制方法:中国,CN201310674404.4[P].2013-12-13.
  • 9Aapro M,Crawford J,Kamioner D.Prophylax is of chemotherapy-induced febrile neutropenia with granulocyte colony-stimu lating fact ors:where are we now?[J].Support Care Cancer,2010,18:529-541.
  • 10Brouwers M,Kho ME,Browman GP,et al.AGREE Ⅱ:Advancing guideline development,reporting and evaluation in healthcare[J].Can Med Assoc,2010,182(19):839-842.

引证文献20

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部